BCAX
Bicara Therapeutics

80
Loading...
Loading...
News
all
press releases
Wedbush Reaffirms Outperform Rating for Bicara Therapeutics (NASDAQ:BCAX)
Wedbush reiterated an "outperform" rating and issued a $30.00 target price on shares of Bicara Therapeutics in a research note on Tuesday...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Bicara Therapeutics Touts Breakthrough Ficerafusp Data, Picks 1,500 mg Dose for FORTIFY-HNS Trial
Bicara Therapeutics (NASDAQ:BCAX) used its presentation at the 44th Annual J.P. Morgan Healthcare Conference to outline its 2026 corporate outlook and highlight 2025 milestones centered on its lead...
MarketBeat·3d ago
News Placeholder
Bicara Therapeutics (NASDAQ:BCAX) Shares Down 7% - Time to Sell?
Bicara Therapeutics (NASDAQ:BCAX) Trading Down 7% - What's Next...
MarketBeat·3d ago
News Placeholder
Bicara Therapeutics (NASDAQ:BCAX) Trading Up 7.8% - Here's Why
Bicara Therapeutics (NASDAQ:BCAX) Shares Up 7.8% - Here's What Happened...
MarketBeat·7d ago
News Placeholder
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Rating of "Hold" from Analysts
Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) have been given an average rating of "Hold" by the seven ratings firms that are presently covering the company, Marketbeat Ratings...
MarketBeat·11d ago
News Placeholder
Bicara Therapeutics (NASDAQ:BCAX) Stock Price Up 3.9% - Still a Buy?
Bicara Therapeutics (NASDAQ:BCAX) Trading 3.9% Higher - Here's Why...
MarketBeat·16d ago
News Placeholder
Bicara Therapeutics (NASDAQ:BCAX) Raised to "Hold" at Mizuho
Mizuho upgraded shares of Bicara Therapeutics to a "hold" rating in a research report on Thursday...
MarketBeat·28d ago
News Placeholder
Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) COO Sells 12,500 Shares of Stock
Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) COO Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock in a transaction that occurred on Monday, December 15th. The shares were...
MarketBeat·1mo ago
News Placeholder
Bicara Therapeutics (NASDAQ:BCAX) COO Ryan Cohlhepp Sells 12,500 Shares
Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) COO Ryan Cohlhepp sold 12,500 shares of the firm's stock in a transaction on Monday, December 15th. The stock was sold at an average price of...
MarketBeat·1mo ago
News Placeholder
Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Average Recommendation of "Moderate Buy" by Brokerages
Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the six brokerages that are covering the company, MarketBeat Ratings reports. One...
MarketBeat·1mo ago
<
1
2
...
>

Latest BCAX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.